NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
BeOne Medicines Ltd. ONC
12 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 5.3B
Revenue, FY2025 · full 12-year series below
Revenue $B
Net income $B
FY2025 · Revenue 5.3 · Net income 0.3
Compound annual growth
Revenue compounded at +76.8% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
5 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 8.4% · Net 5.4%
ROE
FY2025 · ROE 7.5%
Each USD of equity produced 7 cents of profit this year.
The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 5.3 | 3.8 | 2.5 | 1.4 | 1.2 | 0.3 | 0.4 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 |
| Operating income $B | 0.4 | −0.6 | −1.2 | −1.8 | −1.4 | −1.7 | −1.0 | −0.7 | −0.1 | −0.1 | −0.1 | −0.0 |
| EBITDA $B | 0.6 | −0.4 | −1.1 | −1.7 | −1.4 | −1.6 | −0.9 | −0.7 | −0.1 | −0.1 | −0.1 | −0.0 |
| Income tax $B | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | 0.3 | −0.6 | −0.9 | −2.0 | −1.5 | −1.6 | −0.9 | −0.7 | −0.1 | −0.1 | −0.1 | −0.0 |
| Free cash flow $B | 0.9 | −0.6 | −1.7 | −1.8 | −1.6 | −1.4 | −0.8 | −0.6 | −0.0 | −0.1 | −0.0 | −0.0 |
| EPS, diluted $ | 0.19 | −0.47 | −0.65 | −1.49 | −1.21 | −1.50 | −1.22 | −0.93 | −0.17 | −0.30 | −0.52 | −0.18 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 7.5 | −18.8 | −22.3 | −38.1 | −29.2 | −67.3 | −70.2 | −55.9 | −18.2 | −94.9 | · | · |
| Shares out B | 1.44 | 1.39 | 1.36 | 1.36 | 1.33 | 1.19 | 0.80 | 0.78 | 0.59 | 0.52 | 0.12 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 46 reconciliationsAUDITED
Reconciled in 12 of 19 fiscal years. 42 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2014